Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Cancer Genome Landscapes

B. Vogelstein, N. Papadopoulos, V. Velculescu, S. Zhou, L. Diaz, K. Kinzler
Published 2013 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Over the past decade, comprehensive sequencing efforts have revealed the genomic landscapes of common forms of human cancer. For most cancer types, this landscape consists of a small number of “mountains” (genes altered in a high percentage of tumors) and a much larger number of “hills” (genes altered infrequently). To date, these studies have revealed ~140 genes that, when altered by intragenic mutations, can promote or “drive” tumorigenesis. A typical tumor contains two to eight of these “driver gene” mutations; the remaining mutations are passengers that confer no selective growth advantage. Driver genes can be classified into 12 signaling pathways that regulate three core cellular processes: cell fate, cell survival, and genome maintenance. A better understanding of these pathways is one of the most pressing needs in basic cancer research. Even now, however, our knowledge of cancer genomes is sufficient to guide the development of more effective approaches for reducing cancer morbidity and mortality.
This paper references
Curr. Opin. Hematol
W S Pear (2004)
10.1056/NEJMoa1005143
DNMT3A mutations in acute myeloid leukemia.
T. Ley (2010)
Cancer Res
J C Castle (2012)
10.1038/ng.2391
Exome sequencing of hepatitis B virus–associated hepatocellular carcinoma
J. Huang (2012)
Cold Spring Harb. Perspect. Biol
N Perrimon (2012)
N. Engl. J. Med
R S Kerbel (2008)
10.3322/caac.20132
Immunotherapy of cancer in 2012
J. Kirkwood (2012)
10.1634/theoncologist.2010-S1-36
Ethical and value issues in insurance coverage for cancer treatment.
D. Brock (2010)
10.1038/nature11125
The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer
C. Grasso (2012)
Popul. Biol
R Durrett (2010)
Br. J. Cancer
M. Gerretsen (1993)
10.2174/138161212799436449
Computational drug design targeting protein-protein interactions.
R. Bienstock (2012)
10.1126/science.1198056
The Genetic Landscape of the Childhood Cancer Medulloblastoma
D. Parsons (2011)
10.1038/NG0796-343
Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers
S. Thiagalingam (1996)
10.1093/JNCI/85.13.1058
Genetic heterogeneity of the c-K-ras locus in colorectal adenomas but not in adenocarcinomas.
D. Shibata (1993)
N. Engl. J. Med
E L Kwak (2010)
Nat. Rev. Drug Discov
M R Arkin (2004)
10.1056/NEJMoa1113205
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.
M. Gerlinger (2012)
10.1038/nature11219
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
L. Diaz (2012)
10.1016/j.cell.2007.01.029
The Epigenomics of Cancer
P. Jones (2007)
10.1590/S0034-89102010000400005
Uso racional de medicamentos antineoplásicos y acciones judiciales en el estado de Sao Paulo, Sureste de Brasil
L. C. Lopes (2010)
10.1038/nbt.2379
The mouse lymph node as an ectopic transplantation site for multiple tissues
J. Komori (2012)
N. Engl. J. Med
F S Hodi (2010)
Nucleic Acids Res
T Barrett (2011)
J. Clin. Oncol
J H Sampson (2010)
疟原虫var基因转换速率变化导致抗原变异[英]/Paul H, Robert P, Christodoulou Z, et al//Proc Natl Acad Sci U S A
宁北芳 (2005)
10.1038/nrc1435
Transcription — guarding the genome by sensing DNA damage
M. Ljungman (2004)
Mutat. Res
M Gundry (2012)
Nat. Rev. Cancer
N Turner (2010)
10.1002/humu.21633
Somatic Mutations in the Chromatin Remodeling Gene ARID1A Occur in Several Tumor Types
S. Jones (2012)
10.1038/ng.982
Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer
K. Wang (2011)
10.1093/bfgp/elr033
Targeted enrichment of genomic DNA regions for next-generation sequencing
Florian Mertes (2011)
10.1038/nature11412
Comprehensive molecular portraits of human breast tumors
D. Koboldt (2012)
10.1016/j.cell.2012.01.058
Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism
H. Ying (2012)
10.1038/nature03445
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H. Farmer (2005)
10.1126/science.1196333
Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma
S. Jones (2010)
10.1016/j.cell.2012.02.025
Single-Cell Exome Sequencing Reveals Single-Nucleotide Mutation Characteristics of a Kidney Tumor
X. Xu (2012)
10.1093/nar/gks836
From next-generation sequencing alignments to accurate comparison and validation of single-nucleotide variants: the pibase software
M. Forster (2013)
10.1158/0008-5472.CAN-12-2273
Single-molecule genomic data delineate patient-specific tumor profiles and cancer stem cell organization.
A. Sottoriva (2013)
Nat. Rev. Cancer
A P Feinberg (2004)
J. Clin. Oncol
N Wagle (2011)
10.1105/tpc.10.11.1771
Genomics
R. Quatrano (1998)
10.1038/ng.2503
Germline mutations in the proof-reading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas
C. Palles (2013)
10.1126/science.1230184
Epigenetic Reprogramming in Cancer
Mario L. Suvà (2013)
10.1016/S0065-230X(08)60469-8
Growth dominance of the metastatic cancer cell: cellular and molecular aspects.
R. Kerbel (1990)
10.1016/0092-8674(90)90186-I
A genetic model for colorectal tumorigenesis
E. Fearon (1990)
N. Engl. J. Med
K C Wiegand (2010)
10.1126/SCIENCE.281.5382.1509
Identification of c-MYC as a target of the APC pathway.
T. He (1998)
10.1083/jcb.201010021
Circulating tumor cells: approaches to isolation and characterization
M. Yu (2011)
10.1056/NEJMoa1200690
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
S. Topalian (2012)
Nat. Genet
S Thiagalingam (1996)
Nucleic Acids Res
J S Kaminker (2007)
10.1016/j.cell.2012.04.023
The Life History of 21 Breast Cancers
S. Nik-Zainal (2012)
Nat. Rev. Cancer
S V Sharma (2007)
Nat. Rev. Cancer
M Ljungman (2004)
Cancer Res
H Pang (2009)
10.1093/nar/gkq1184
NCBI GEO: archive for functional genomics data sets—10 years on
T. Barrett (2011)
10.1111/j.1749-6632.2012.06577.x
Molecular and functional characterization of early human hematopoiesis
E. Laurenti (2012)
10.1126/SCIENCE.1102160
Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia
A. Weng (2004)
10.1200/JCO.2010.33.2312
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.
N. Wagle (2011)
10.1101/cshperspect.a005975
Signaling mechanisms controlling cell fate and embryonic patterning.
N. Perrimon (2012)
Nucleic Acids Res. 2013; 41:e16
M Forster (2013)
Cancer Res
N H Segal (2008)
10.1038/nature10803
Expression of tumour-specific antigens underlies cancer immunoediting
Michel DuPage (2012)
10.1126/science.1160809
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
M. V. Vander Heiden (2009)
10.1038/35044005
The DNA damage response: putting checkpoints in perspective
B. Zhou (2000)
10.1038/sj.bjc.6602297
The Age Distribution of Cancer and a Multi-stage Theory of Carcinogenesis
P. Armitage (2004)
10.1126/science.1207313
Altered Telomeres in Tumors with ATRX and DAXX Mutations
C. Heaphy (2011)
10.1101/gr.125567.111
Mutual exclusivity analysis identifies oncogenic network modules.
Giovanni Ciriello (2012)
Ann. N.Y. Acad. Sci
E Laurenti (2012)
10.1590/S0034-89102010000400005
Rational use of anticancer drugs and patient lawsuits in the state of São Paulo, Southeastern Brazil.
L. Lopes (2010)
10.1038/nature10496
Frequent pathway mutations of splicing machinery in myelodysplasia
K. Yoshida (2011)
10.1016/S0165-4608(01)00645-8
Coping with complexity. multivariate analysis of tumor karyotypes.
M. Höglund (2002)
Cancer Chemother. Pharmacol
J Chen (2013)
Expert Rev. Anticancer Ther
S Irshad (2011)
10.1126/scitranslmed.3003218
Applying What We Know to Accelerate Cancer Prevention
G. Colditz (2012)
Clin. Cancer Res
M Mao (2013)
Curr. Pharm. Des
R J Bienstock (2012)
Adv. Cancer Res
R S Kerbel (1990)
10.1038/ng.1031
RECURRENT MUTATIONS IN THE U2AF1 SPLICING FACTOR IN MYELODYSPLASTIC SYNDROMES
T. Graubert (2012)
10.1016/j.mrrev.2011.11.002
Whole genome sequencing for quantifying germline mutation frequency in humans and model species: cautious optimism.
M. Beal (2012)
10.1038/ng1099
Notch1 functions as a tumor suppressor in mouse skin
M. Nicolas (2003)
10.1016/j.febslet.2010.10.061
The DNA methylome
Mattia Pelizzola (2011)
10.1038/nature11252
Comprehensive Molecular Characterization of Human Colon and Rectal Cancer
D. M. Muzny (2012)
Cancer Res
H Carter (2009)
Gabelli for assisting with the production
M. Nowak (2012)
Annu. Rev. Cell Dev. Biol
A S Chung (2011)
10.1158/0008-5472.CAN-09-1968
Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase.
Huan Pang (2009)
10.1038/onc.2011.451
Checkpoint control and cancer
R. Medema (2012)
Cancer Res
A Sottoriva (2013)
10.1038/nature10860
IDH mutation impairs histone demethylation and results in a block to cell differentiation
C. Lu (2012)
10.1002/path.4132
Whole-genome methylation analysis of benign and malignant colorectal tumours
A. Beggs (2013)
10.1038/nature09460
The patterns and dynamics of genomic instability in metastatic pancreatic cancer
P. Campbell (2010)
10.1038/ng.2405
Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer
C. Rudin (2012)
Cancer Discovery
N Agrawal (2013)
This copy is for your personal, non-commercial use only.
Seon-hee Kim (2014)
Surgery
W. M. Barclay (1894)
10.1126/science.1230062
TERT Promoter Mutations in Familial and Sporadic Melanoma
S. Horn (2013)
10.1038/nature11017
The landscape of cancer genes and mutational processes in breast cancer
P. Stephens (2012)
10.1016/j.cell.2010.11.055
Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer Development
P. Stephens (2011)
10.1158/2159-8290.CD-12-0189
Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma.
N. Agrawal (2012)
10.1158/0008-5472.CAN-11-3722
Exploiting the mutanome for tumor vaccination.
J. Castle (2012)
10.1158/0008-5472.CAN-04-1198
A quantitative measurement of the human somatic mutation rate.
D. Araten (2005)
10.1038/nature10833
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
J. Schwartzentruber (2012)
10.1016/0092-8674(93)90586-F
Cell
AC Tose (1993)
10.1038/nature11143
Whole Genome Analysis Informs Breast Cancer Response to Aromatase Inhibition
M. Ellis (2012)
Nucleic Acids Res
S A Forbes (2011)
Nat. Biotechnol
J Komori (2012)
N. Engl. J. Med
M Gerlinger (2012)
10.5694/j.1326-5377.1924.tb66156.x
THE CANCER CELL
A. Chadli (1963)
Nat. Rev. Genet
M Meyerson (2010)
10.1073/pnas.0808019105
Kinase requirements in human cells: I. Comparing kinase requirements across various cell types
D. Grueneberg (2008)
10.1056/NEJMoa1006448
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
Eunice L. Kwak (2010)
10.1056/NEJMoa1103283
Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts.
E. Papaemmanuil (2011)
10.1097/01.moh.0000143965.90813.70
T cell acute lymphoblastic leukemia/lymphoma: a human cancer commonly associated with aberrant NOTCH1 signaling
W. Pear (2004)
Sci. Transl. Med
G A Colditz (2012)
10.1038/nrg2763
Alternative lengthening of telomeres: models, mechanisms and implications
Anthony J. Cesare (2010)
10.1038/nrd1343
Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
M. Arkin (2004)
10.1126/science.1170944
Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α
S. Zhao (2009)
10.1007/978-3-642-10858-7_3
Biomarkers for early detection and as surrogate endpoints in cancer prevention trials: issues and opportunities.
B. Dunn (2011)
10.1016/j.ygeno.2008.07.005
Design and analysis issues in genome-wide somatic mutation studies of cancer.
G. Parmigiani (2009)
N. Engl. J. Med
P B Chapman (2011)
10.4135/9781412952644.n56
“Bioinformatics” 특집을 내면서
장병탁 (2000)
10.1038/nrc1609
ERBB receptors and cancer: the complexity of targeted inhibitors
N. Hynes (2005)
10.1016/S0092-8674(02)01014-0
The β-Catenin/TCF-4 Complex Imposes a Crypt Progenitor Phenotype on Colorectal Cancer Cells
M. Wetering (2002)
10.1038/nrg2841
Advances in understanding cancer genomes through second-generation sequencing
M. Meyerson (2010)
10.1126/SCIENCE.1117679
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
S. Tomlins (2005)
10.1126/science.1164382
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
D. Parsons (2008)
10.1146/annurev-cellbio-092910-154002
Developmental and pathological angiogenesis.
A. Chung (2011)
Recent Results Cancer Res
B K Dunn (2011)
Nucleic Acids Res
R Böttcher (2012)
Nat. Genet
C Palles (2013)
10.1067/MSY.2001.112738
Microsatellite instability, mismatch repair deficiency, and colorectal cancer.
R. Gryfe (2001)
10.1056/NEJMoa0810069
Mutation in TET2 in myeloid cancers.
F. Delhommeau (2009)
10.1038/418823a
Metastasis genes: A progression puzzle
R. Bernards (2002)
The Cancer Genome Atlas Network
(2012)
N. Engl. J. Med
S L Topalian (2012)
Oncologist
D W Brock (2010)
10.1073/pnas.1018154108
Scaling rules for diffusive drug delivery in tumor and normal tissues
J. W. Baish (2011)
10.1038/nature09807
Tumour evolution inferred by single-cell sequencing
N. Navin (2011)
10.1126/science.1200609
DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors
Y. Jiao (2011)
10.1016/J.MRFMMM.2011.10.001
Direct mutation analysis by high-throughput sequencing: from germline to low-abundant, somatic variants
Michael Gundry (2012)
10.1126/science.1229259
Highly Recurrent TERT Promoter Mutations in Human Melanoma
F. Huang (2013)
10.1038/nature08672
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes
Gillian L. Dalgliesh (2010)
10.1126/science.1234139
Cancer Pharmacogenomics: Early Promise, But Concerted Effort Needed
H. McLeod (2013)
10.1016/j.ccr.2010.01.020
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
Patrick S Ward (2010)
N. Engl. J. Med
H Yan (2009)
10.1016/j.cell.2012.06.023
The Origin and Evolution of Mutations in Acute Myeloid Leukemia
J. Welch (2012)
10.1093/nar/gks393
Using a priori knowledge to align sequencing reads to their exact genomic position
R. Böttcher (2012)
10.1177/1534650105277713
Ann
Ericka Stricklin-Parker (2005)
10.1093/nar/gkm405
CanPredict: a computational tool for predicting cancer-associated missense mutations
Joshua S. Kaminker (2007)
10.1038/nature10866
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Ş. Turcan (2012)
Brief. Funct. Genomics
F Mertes (2011)
Nat. Genet
J Huang (2012)
10.1096/fj.08-108985
Combinatorial patterns of somatic gene mutations in cancer
C. Yeang (2008)
10.1073/PNAS.0501870102
Drug resistance in cancer: principles of emergence and prevention.
N. Komarova (2005)
10.1038/ng.1102
Somatic Histone H3 Alterations in Paediatric Diffuse Intrinsic Pontine Gliomas and Non-Brainstem Glioblastomas
G. Wu (2012)
J. Cell Biol
M Yu (2011)
10.1038/ng.936
Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion
A. Bass (2011)
10.1158/1078-0432.CCR-11-1446
Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents
M. Mao (2012)
10.1073/pnas.1010978107
Accumulation of driver and passenger mutations during tumor progression
I. Bozic (2010)
10.1016/j.cell.2012.11.019
Whole-Genome Sequencing in Autism Identifies Hot Spots for De Novo Germline Mutation
J. Michaelson (2012)
10.1007/s00280-012-2005-9
Association between KRAS codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta-analysis
J. Chen (2012)
10.1016/j.ccr.2011.11.006
Combined genetic inactivation of β2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma.
Madhavi Challa-Malladi (2011)
10.1016/j.ccr.2009.11.022
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.
Alexa B. Turke (2010)
10.1038/386761A0
Gatekeepers and caretakers
K. Kinzler (1997)
10.1126/science.1219580
Recurrent Hemizygous Deletions in Cancers May Optimize Proliferative Potential
N. Solimini (2012)
Mutat. Res
M A Beal (2012)
Nat. Genet
M Nicolas (2003)
10.1016/j.otohns.2009.05.016
Nature
R. Rosenfeld (2009)
Nucleic Acids Res
M Forster (2013)
Hum. Mutat
S Jones (2012)
10.1158/0008-5472.CAN-07-3095
Epitope landscape in breast and colorectal cancer.
N. Segal (2008)
10.1016/j.devcel.2008.01.013
CDK inhibitors: cell cycle regulators and beyond.
A. Besson (2008)
10.1200/JCO.2010.28.6963
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.
J. Sampson (2010)
10.1016/j.tpb.2009.10.008
Evolution of resistance and progression to disease during clonal expansion of cancer.
R. Durrett (2010)
10.1038/nrc2780
Fibroblast growth factor signalling: from development to cancer
N. Turner (2010)
10.1038/nature09515
Distant Metastasis Occurs Late during the Genetic Evolution of Pancreatic Cancer
S. Yachida (2010)
10.1126/science.1227670
Variable Clonal Repopulation Dynamics Influence Chemotherapy Response in Colorectal Cancer
A. Krešo (2013)
10.1016/j.cell.2010.06.011
Cell Signaling by Receptor Tyrosine Kinases
M. Lemmon (2010)
10.1158/0008-5472.CAN-09-1133
Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations.
H. Carter (2009)
10.1126/SCIENCE.289.5486.1890
Genetic Testing-- Present and Future
H. Yan (2000)
10.1126/SCIENCE.275.5307.1787
Activation of β-Catenin-Tcf Signaling in Colon Cancer by Mutations in β-Catenin or APC
P. Morin (1997)
10.1073/pnas.1221068110
Half or more of the somatic mutations in cancers of self-renewing tissues originate prior to tumor initiation
C. Tomasetti (2013)
J. Natl. Cancer Inst
D Shibata (1993)
Nat. Genet
K Wang (2011)
10.1016/j.febslet.2010.05.031
Multiple roles of ATM in monitoring and maintaining DNA integrity
Frederick A Derheimer (2010)
10.1038/nrc1279
The history of cancer epigenetics
A. Feinberg (2004)
Nucleic Acids Res. 2012; 40:e125
R Böttcher (2012)
Rev Saúde Pública
Roberta Pereira NiquiniI (2010)
10.1016/j.cell.2012.08.029
Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
M. Imielinski (2012)
10.1126/science.1208130
The Mutational Landscape of Head and Neck Squamous Cell Carcinoma
Nicolas Stransky (2011)
10.1038/nature09650
Genetic variegation of clonal architecture and propagating cells in leukaemia
K. Anderson (2011)
10.1101/sqb.2009.74.027
Evolving views of DNA replication (in)fidelity.
T. Kunkel (2009)
10.1126/SCIENCE.959840
The clonal evolution of tumor cell populations.
P. Nowell (1976)
10.1056/NEJMoa0808710
IDH1 and IDH2 mutations in gliomas.
H. Yan (2009)
10.1056/NEJMoa1008433
ARID1A mutations in endometriosis-associated ovarian carcinomas.
Kimberly C. Wiegand (2010)
10.1586/era.11.52
Therapeutic potential of PARP inhibitors for metastatic breast cancer
S. Irshad (2011)
10.1016/j.cell.2012.04.024
Mutational Processes Molding the Genomes of 21 Breast Cancers
S. Nik-Zainal (2012)
10.1126/science.1164368
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
S. Jones (2008)
J. Pathol
A D Beggs (1002)
10.1038/nrc2088
Epidermal growth factor receptor mutations in lung cancer
S. Sharma (2007)
10.1073/pnas.0712345105
Comparative lesion sequencing provides insights into tumor evolution
S. Jones (2008)
10.1038/nature11547
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes
A. Biankin (2012)
10.1056/NEJMoa1003466
Improved survival with ipilimumab in patients with metastatic melanoma.
F. S. Hodi (2010)
Nat. Genet
L Pasqualucci (2011)
Dev. Cell
A Besson (2008)
10.1038/nature08489
Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution
S. Shah (2009)
10.1093/nar/gkq929
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
S. Forbes (2011)
10.1038/nature10755
Cancer Exome Analysis Reveals a T Cell Dependent Mechanism of Cancer Immunoediting
H. Matsushita (2012)
10.1038/nature08617
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
L. Dang (2009)
Nat. Genet
A J Bass (2011)
CA Cancer J. Clin
J M Kirkwood (2012)
Cancer Genet Cytogenet
M Höglund (2013)
Nat. Rev. Cancer
N E Hynes (2005)
10.1016/j.cell.2012.08.024
Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers
R. Govindan (2012)
10.1093/bioinformatics/btr629
Feature-based classifiers for somatic mutation detection in tumour–normal paired sequencing data
Jiarui Ding (2012)
10.1038/nature10351
Frequent mutation of histone modifying genes in non-Hodgkin lymphoma
R. Morin (2011)
10.1056/NEJMoa1103782
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
P. Chapman (2011)
10.1126/science.1206923
Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1
N. Agrawal (2011)
10.1073/pnas.1206062109
A cluster of cooperating tumor-suppressor gene candidates in chromosomal deletions
W. Xue (2012)
10.1093/bioinformatics/btq630
Identifying cancer driver genes in tumor genome sequencing studies
A. Youn (2011)
10.1038/nature05945
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
M. Soda (2007)
10.1038/ng.892
Analysis of the Coding Genome of Diffuse Large B-Cell Lymphoma
L. Pasqualucci (2011)
10.1126/science.1174229
Glucose Deprivation Contributes to the Development of KRAS Pathway Mutations in Tumor Cells
Jihye Yun (2009)



This paper is referenced by
10.18632/oncotarget.25087
Transcriptome based individualized therapy of refractory pediatric sarcomas: feasibility, tolerability and efficacy
B. Weidenbusch (2018)
10.1016/j.celrep.2013.11.033
Recessive cancer genes engage in negative genetic interactions with their functional paralogs.
M. D'Antonio (2013)
10.1016/j.ijpharm.2017.01.068
Core-interlayer-shell Fe3O4@mSiO2@lipid-PEG-methotrexate nanoparticle for multimodal imaging and multistage targeted chemo-photodynamic therapy.
Guihua Liu (2017)
10.1002/sim.6066
Detection of candidate tumor driver genes using a fully integrated Bayesian approach.
Jichen Yang (2014)
10.1111/cas.13510
Understanding intratumor heterogeneity by combining genome analysis and mathematical modeling
A. Niida (2018)
Prognostic and therapeutic implications of DNA repair gene mutations in advanced prostate cancer.
M. Schweizer (2017)
10.21037/tlcr.2018.08.02
Methods of measurement for tumor mutational burden in tumor tissue.
Bárbara Meléndez (2018)
10.1007/s00761-013-2495-z
Molekulare Bildgebung und pathologische Diagnostik
Bernhard Riemann (2013)
Charting the Genetic Landscape and Clonal Architectures of Pheochromocytoma
Joakim Crona (2014)
10.1016/B978-0-12-801238-3.02220-0
DNA Repair Mechanisms and Initiation in Carcinogenesis: An Update
Dietrich Averbeck (2014)
10.1038/NMETH.2777
In situ sequencing
Tal Nawy (2013)
10.7243/2052-6199-1-7
Cancer stem cells and addicted cancer cells
Meike E. W. Logtenberg (2013)
10.1016/B978-0-12-409547-2.12326-1
Small-Molecule Inhibitors of Protein–Protein Interactions
Li Shan Zhou (2016)
Bioinformatic identification of disease driver networks using functional profiling data
Agnieszka Szwajda (2018)
10.3892/ol.2018.9866
Integrative analysis of gene expression profiles reveals distinct molecular characteristics in oral tongue squamous cell carcinoma
Ranran Wang (2019)
10.1007/s10549-018-4965-x
Epigenetic modulation of FOXM1-gene interacting network by BET inhibitors in breast cancer
J. Pérez-Peña (2018)
RE: Comments on the NTP TECHNICAL REPORT ON THE TOXICOLOGY STUDIES OF TETRABROMOBISPHENOL A (CAS NO. 79-94-7) IN F344/NTac RATS AND B6C3F1/N MICE AND TOXICOLOGY AND CARCINOGENESIS STUDIES OF TETRABROMOBISPHENOL A IN WISTAR HAN [Crl:WI(Han)] RATS AND B6C3F1/N
L. White (2013)
The effect of the polyadenylation inhibitor Cordycepin on MCF-7 cells
Asma Khurshid (2015)
Pax 5 loss imposes a reversible differentiation block in B-progenitor acute lymphoblastic leukemia
G. J. Liu (2014)
Simultaneous Integration of Multi-omics Data Improves the Identification of Cancer DriverModules Graphical
Dana Silverbush (2019)
Altered Expression of Kinetochore Proteins (CENP-A and Mad2) to Explore Chromosome Instability and Aneuploidy
Katherine J. Aney (2018)
CMAR_A_199817 3187..3196
Li-ya Wei (2019)
OTT_A_226202 9459..9471
Chenxin Xu (2019)
10.1101/129478
Transcription factor activities enhance markers of drug response in cancer
Luz Garcia-Alonso (2017)
10.1080/14737159.2017.1319280
Barriers preventing the adoption of comprehensive cancer genomic profiling in the clinic
C. Statz (2017)
Retrospective case series and literature review
Jingjing Li (2020)
10.3389/fcell.2019.00079
The Good, the Bad and the Tick
A. Cabezas-Cruz (2019)
10.1007/s12254-016-0292-2
PD-L1 testing, fit for routine evaluation? From a pathologist’s point of view
G. Hutarew (2016)
10.20517/2394-4722.2018.31
Immunotherapy in the treatment of colorectal cancer: a new kid on the block
A. Spallanzani (2018)
10.5005/JP-JOURNALS-10015-1388
Somatic Mutation Theory/Tissue Organization Field Theory: Has the Premise been Wrong All along?
S. Sarode (2016)
10.1002/hep.27442
Rethinking cancer immunotherapy: Using advanced cancer genetics in immune‐mediated eradication of gastrointestinal cancers
Alexander G. Miamen (2014)
10.1002/9781118795569.CH5
From chromosomes to genes
I. Panagopoulos (2015)
See more
Semantic Scholar Logo Some data provided by SemanticScholar